Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam L Boxer

Showing results (11-20 of 300) with videos related to

Pageof 30
Sort By:
Current Treatment Options in Neurology|September 21, 2014
Treatment of frontotemporal dementiaRichard M Tsai, Adam L Boxer
Journal of Neurochemistry|June 17, 2016
Therapy and clinical trials in frontotemporal dementia: past, present, and futureRichard M Tsai, Adam L Boxer
The Clinical Neuropsychologist|September 28, 2019
Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsyKevin Duff, Christopher Randolph, Adam L Boxer
Neuroscience Letters|May 8, 2020
Targeting tau: Clinical trials and novel therapeutic approachesLawren VandeVrede, Adam L Boxer, Manuela Polydoro
The Lancet. Neurology|July 19, 2024
Clinical versus biomarker-based diagnosis of neurocognitive disordersGünter U Höglinger, Adam L Boxer, Anthony E Lang
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDSHoward J Rosen, Bradley F Boeve, Adam L Boxer
Frontiers in Neurology|September 25, 2018
24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal SyndromeIngemar Björkhem, Kalicharan Patra, Adam L Boxer, et al.
The Journal of Clinical Investigation|June 15, 2023
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenuesNiyatee Samudra, Courtney Lane-Donovan, Lawren VandeVrede, et al.
Journal of Clinical and Experimental Neuropsychology|February 5, 2019
Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological StatusKevin Duff, Dana McDermott, Dan Luong, et al.
Frontiers in Neurology|January 7, 2021
Associations Between Amantadine Usage, Gait, and Cognition in PSP: A <i>post-hoc</i> Analysis of the Davunetide TrialMarian L Dale, Barbara H Brumbach, Adam L Boxer, et al.
Pageof 30

Showing results (11-20 of 300) with videos related to

Sort By:
Pageof 30
Current Treatment Options in Neurology|September 21, 2014
Treatment of frontotemporal dementiaRichard M Tsai, Adam L Boxer
Journal of Neurochemistry|June 17, 2016
Therapy and clinical trials in frontotemporal dementia: past, present, and futureRichard M Tsai, Adam L Boxer
The Clinical Neuropsychologist|September 28, 2019
Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsyKevin Duff, Christopher Randolph, Adam L Boxer
Neuroscience Letters|May 8, 2020
Targeting tau: Clinical trials and novel therapeutic approachesLawren VandeVrede, Adam L Boxer, Manuela Polydoro
The Lancet. Neurology|July 19, 2024
Clinical versus biomarker-based diagnosis of neurocognitive disordersGünter U Höglinger, Adam L Boxer, Anthony E Lang
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDSHoward J Rosen, Bradley F Boeve, Adam L Boxer
Frontiers in Neurology|September 25, 2018
24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal SyndromeIngemar Björkhem, Kalicharan Patra, Adam L Boxer, et al.
The Journal of Clinical Investigation|June 15, 2023
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenuesNiyatee Samudra, Courtney Lane-Donovan, Lawren VandeVrede, et al.
Journal of Clinical and Experimental Neuropsychology|February 5, 2019
Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological StatusKevin Duff, Dana McDermott, Dan Luong, et al.
Frontiers in Neurology|January 7, 2021
Associations Between Amantadine Usage, Gait, and Cognition in PSP: A <i>post-hoc</i> Analysis of the Davunetide TrialMarian L Dale, Barbara H Brumbach, Adam L Boxer, et al.
Pageof 30